Rani Therapeutics CTO granted 805,500 stock options

Rani Therapeutics Holdings, Inc. reported that Chief Technical Officer Alireza Javadi received a grant of stock options covering 805,500 shares of Class A common stock.

Rhea-AI Filing Summary

Rani Therapeutics Holdings, Inc. reported that Chief Technical Officer Alireza Javadi received a grant of stock options covering 805,500 shares of Class A common stock. The options have an exercise price of $0.875 per share and expire on June 2, 2036.

According to the grant terms, 1/48th of the options vest monthly over four years starting April 1, 2026, as long as he maintains continuous service with the company. This is a compensation-related award, not an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 805,500 shares

Grant/Award 1 txn

Insider Javadi Alireza

Role Chief Technical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	805,500	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 805,500 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from April 1, 2026, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through each such vesting date.

Key Figures

Option grant size: 805,500 options Exercise price: $0.875 per share Expiration date: June 2, 2036 +4 more

7 metrics

Option grant size 805,500 options Total options awarded to CTO in this grant

Exercise price $0.875 per share Strike price for Class A common stock under the option

Expiration date June 2, 2036 Option term end date

Underlying shares 805,500 shares Class A common stock underlying the option

Vesting start April 1, 2026 Commencement of monthly vesting schedule

Vesting schedule 1/48th monthly over 4 years Subject to continuous service requirement

Post-transaction derivative holdings 805,500 options Total derivative securities held after this grant

Key Terms

Stock Option (Right to Buy), Class A Common Stock, Continuous Service, 2021 Equity Incentive Plan, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Class A Common Stock financial

"underlying_security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Continuous Service financial

"subject to the Reporting Person's Continuous Service"

2021 Equity Incentive Plan financial

"as defined in the Company's 2021 Equity Incentive Plan"

vesting financial

"1/48th of the shares subject to the option vest monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Rani Therapeutics (RANI) disclose in this Form 4 for its CTO?

Rani Therapeutics disclosed that Chief Technical Officer Alireza Javadi received a grant of 805,500 stock options. These options relate to Class A common stock, have an exercise price of $0.875 per share, and form part of his equity-based compensation package.

How many RANI stock options were granted to CTO Alireza Javadi?

The CTO received stock options for 805,500 shares of Rani Therapeutics Class A common stock. This entire amount was reported as a single grant and represents his total derivative holdings following the reported transaction on the Form 4.

What is the exercise price of the RANI stock options granted to the CTO?

The granted stock options have an exercise price of $0.875 per share. This means Alireza Javadi can buy Rani Therapeutics Class A common stock at $0.875 per share once the options vest and before they expire, subject to plan terms.

When do the newly granted RANI stock options start vesting for the CTO?

The options begin vesting on April 1, 2026. From that date, 1/48th of the total 805,500 options vest monthly over four years, contingent on Alireza Javadi’s continuous service with Rani Therapeutics during each monthly vesting date.

Over what period do the CTO’s RANI stock options vest?

The stock options vest over four years from April 1, 2026. Vesting occurs monthly, with 1/48th of the 805,500 options vesting each month, assuming the CTO satisfies the continuous service requirement under the 2021 Equity Incentive Plan.

When do the RANI stock options granted to the CTO expire?

The stock options granted to the CTO expire on June 2, 2036. He must exercise any vested options before this expiration date; otherwise, any unexercised portion of the grant will lapse according to the stated option terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 06:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Javadi Alireza

(Last) (First) (Middle)

C/O RANI THERAPEUTICS LLC

2051 RINGWOOD AVE

(Street)

SAN JOSE CALIFORNIA 95131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc. [ RANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.875	06/03/2026		A		805,500		(1)	06/02/2036	Class A Common Stock	805,500	$0	805,500	D

Explanation of Responses:

1. The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from April 1, 2026, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through each such vesting date.

	/s/ Svai Sanford, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)